SCHEMBL4652248

SCHEMBL4652248

CCOC(=O)COc1cccc2c1c(C(=O)C(N)=O)c(C)n2Cc1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 19/20 0.81
PLA2G1B P04054 8/20 0.81
PLA2G10 O15496 6/20 0.81
PLA2G5 P39877 5/20 0.81
PLA2G2E Q9NZK7 5/20 0.81
PLA2G2F Q9BZM2 3/20 0.66
PLA2G2D Q9UNK4 3/20 0.66
PLA2G6 O60733 1/20 0.66
PLA2G2C Q5R387 1/20 0.66
PLA2G12B Q9BX93 1/20 0.66
PLA2G12A Q9BZM1 1/20 0.66
PLA2G3 Q9NZ20 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7517757 0.93 PLA2G2A (0.83) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL4653409 0.92 PLA2G2A (0.68) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL818556 0.91 PLA2G2A (0.83) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL6812616 0.90 PLA2G2A (0.82) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL819141 0.90 PLA2G2A (1.00) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL14531294 0.90 PLA2G2A (0.88) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL6694834 0.89 PLA2G2A (0.98) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL6694841 0.89 PLA2G2A (0.98) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL5540844 0.88 PLA2G2A (0.78) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL6694837 0.87 PLA2G2A (0.83) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951315-A2 PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS Ilypsa, Inc. (US) 2008-08-06 EP disclosed
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors ILYPSA, INC. 2007-06-14 US disclosed
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors ILYPSA, INC. 2007-06-14 US disclosed
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors ILYPSA, INC. 2007-06-14 US disclosed
WO-2007056279-A2 PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS ILYPSA, INC. (US) 2007-05-18 WO disclosed
WO-2007056279-A2 PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS ILYPSA, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors PNLIP, PLA2G2E, PLA2G3 PLA2G2A 13/4885PLA2G1B 10/4885PLA2G10 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.